Suppr超能文献

使用概率性定量体外到体内外推的计算工作流程,从ToxCast体外浓度-反应数据推导全氟辛酸的人体体内基准剂量。

Derivation of a Human In Vivo Benchmark Dose for Perfluorooctanoic Acid From ToxCast In Vitro Concentration-Response Data Using a Computational Workflow for Probabilistic Quantitative In Vitro to In Vivo Extrapolation.

作者信息

Loizou George, McNally Kevin, Dorne Jean-Lou C M, Hogg Alex

机构信息

Health and Safety Executive, Harpur Hill, Buxton, United Kingdom.

Scientific Committee and Emerging Risks Unit, European Food Safety Authority, Parma, Italy.

出版信息

Front Pharmacol. 2021 May 11;12:630457. doi: 10.3389/fphar.2021.630457. eCollection 2021.

Abstract

A computational workflow which integrates physiologically based kinetic (PBK) modeling, global sensitivity analysis (GSA), approximate Bayesian computation (ABC), and Markov Chain Monte Carlo (MCMC) simulation was developed to facilitate quantitative to extrapolation (QIVIVE). The workflow accounts for parameter and model uncertainty within a computationally efficient framework. The workflow was tested using a human PBK model for perfluorooctanoic acid (PFOA) and high throughput screening (HTS) concentration-response data, determined in a human liver cell line, from the ToxCast/Tox21 database. benchmark doses (BMDs) for PFOA intake (ng/kg BW/day) and drinking water exposure concentrations (µg/L) were calculated from the dose responses and compared to intake values derived by the European Food Safety Authority (EFSA). The intake benchmark dose lower confidence limit (BMDL) of 0.82 was similar to 0.86 ng/kg BW/day for altered serum cholesterol levels derived by EFSA, whereas the intake BMDL of 6.88 was six-fold higher than the value of 1.14 ng/kg BW/day for altered antibody titer also derived by the EFSA. Application of a chemical-specific adjustment factor (CSAF) of 1.4, allowing for inter-individual variability in kinetics, based on biological half-life, gave an intake BMDL of 0.59 for serum cholesterol and 4.91 (ng/kg BW/day), for decreased antibody titer, which were 0.69 and 4.31 the EFSA-derived values, respectively. The corresponding BMDL for drinking water concentrations, for estrogen receptor binding activation associated with breast cancer, pregnane X receptor binding associated with altered serum cholesterol levels, thyroid hormone receptor α binding leading to thyroid disease, and decreased antibody titer (pro-inflammation from cytokines) were 0.883, 0.139, 0.086, and 0.295 ng/ml, respectively, with application of no uncertainty factors. These concentrations are 5.7-, 36-, 58.5-, and 16.9-fold lower than the median measured drinking water level for the general US population which is approximately, 5 ng/ml.

摘要

开发了一种计算工作流程,该流程整合了基于生理学的动力学(PBK)建模、全局敏感性分析(GSA)、近似贝叶斯计算(ABC)和马尔可夫链蒙特卡罗(MCMC)模拟,以促进定量体外外推(QIVIVE)。该工作流程在一个计算效率高的框架内考虑了参数和模型的不确定性。使用针对全氟辛酸(PFOA)的人体PBK模型和来自ToxCast/Tox21数据库的在人肝细胞系中测定的高通量筛选(HTS)浓度响应数据对该工作流程进行了测试。根据剂量反应计算了PFOA摄入量(ng/kg体重/天)和饮用水暴露浓度(μg/L)的基准剂量(BMD),并与欧洲食品安全局(EFSA)得出的摄入量值进行了比较。摄入基准剂量下限(BMDL)为0.82,与EFSA得出的血清胆固醇水平改变的0.86 ng/kg体重/天相似,而摄入BMDL为6.88,比EFSA得出的抗体滴度改变的1.14 ng/kg体重/天的值高六倍。基于生物半衰期应用1.4的化学特异性调整因子(CSAF)以考虑个体间动力学变异性,得出血清胆固醇的摄入BMDL为0.59,抗体滴度降低的摄入BMDL为4.91(ng/kg体重/天),分别为EFSA得出值的0.69和4.31倍。对于与乳腺癌相关的雌激素受体结合活化以及与血清胆固醇水平改变相关的孕烷X受体结合、导致甲状腺疾病的甲状腺激素受体α结合和抗体滴度降低(细胞因子引起的促炎),饮用水浓度的相应BMDL分别为0.883、0.139、0.086和0.295 ng/ml,未应用不确定性因子。这些浓度比美国普通人群的饮用水中位测量水平(约5 ng/ml)低5.7倍、36倍、58.5倍和16.9倍。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/11e6/8144460/25426748b4b8/fphar-12-630457-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验